Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

6.000 +0.780 (+14.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,134,127
Open 4.900
Bid (Size) 6.000 (4)
Ask (Size) 6.100 (2)
Prev. Close 5.220
Today's Range 4.900 - 6.400
52wk Range 3.190 - 6.818
Shares Outstanding 37,953,711
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
DiaMedica Posts Narrower Loss in Q2
Via The Motley Fool
Topics Intellectual Property
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Reports Q2 2025 Earnings: Narrower Loss and Promising Clinical Updates Drive Stock Surge
DiaMedica Therapeutics reports Q2 2025 results with a narrower-than-expected loss, positive clinical updates, and strong cash position. Stock surges 19% post-earnings. 
Via Chartmill

Performance

YTD
+8.9%
+8.9%
1 Month
+49.6%
+49.6%
3 Month
+50.0%
+50.0%
6 Month
-4.5%
-4.5%
1 Year
+67.6%
+67.6%

More News

Read More
DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
From DiaMedica Therapeutics Inc.
Via Business Wire
Exploring DiaMedica Therapeutics's Earnings Expectations
Via Benzinga
Earnings Scheduled For August 12, 2025
Via Benzinga
DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights
From DiaMedica Therapeutics Inc.
Via Business Wire
Insights Ahead: DiaMedica Therapeutics's Quarterly Earnings
Via Benzinga
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update May 14, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
Earnings Scheduled For May 13, 2025
Via Benzinga
Why Ericsson Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results
From DiaMedica Therapeutics Inc.
Via Business Wire
Earnings Scheduled For March 17, 2025
Via Benzinga
DiaMedica Therapeutics to Report Fourth Quarter 2024 Financial Results and Provide a Business Update March 18, 2025
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Appoints Daniel J. O’Connor to the Board of Directors
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
From DiaMedica Therapeutics Inc.
Via Business Wire

Frequently Asked Questions

Is DiaMedica Therapeutics Inc. - Common Stock publicly traded?
Yes, DiaMedica Therapeutics Inc. - Common Stock is publicly traded.
What exchange does DiaMedica Therapeutics Inc. - Common Stock trade on?
DiaMedica Therapeutics Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for DiaMedica Therapeutics Inc. - Common Stock?
The ticker symbol for DiaMedica Therapeutics Inc. - Common Stock is DMAC on the Nasdaq Stock Market
What is the current price of DiaMedica Therapeutics Inc. - Common Stock?
The current price of DiaMedica Therapeutics Inc. - Common Stock is 6.000
When was DiaMedica Therapeutics Inc. - Common Stock last traded?
The last trade of DiaMedica Therapeutics Inc. - Common Stock was at 08/13/25 04:00 PM ET
What is the market capitalization of DiaMedica Therapeutics Inc. - Common Stock?
The market capitalization of DiaMedica Therapeutics Inc. - Common Stock is 227.72M
How many shares of DiaMedica Therapeutics Inc. - Common Stock are outstanding?
DiaMedica Therapeutics Inc. - Common Stock has 228M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.